Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
A phase 2 trial of Pirtobrutinib in non-hodgkin lymphoma, run by Eli Lilly and Company, active and no longer recruiting.
Overview
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers is a phase 2 interventional study registered as NCT07162181 by Eli Lilly and Company, with 13 participants planned, started 2025-08-07 and due to reach its primary completion in 2030-05. Interventions recorded: Pirtobrutinib. Conditions listed: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).
- TrialA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).
- TrialStudy of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).